Difference between revisions of "Mitoxantrone (Novantrone)"
m |
m |
||
| Line 13: | Line 13: | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
*[[Breast cancer]] | *[[Breast cancer]] | ||
| − | |||
*Non-Hodgkin lymphoma | *Non-Hodgkin lymphoma | ||
**[[B-cell lymphoma of mucosa-associated lymphoid tissue]] | **[[B-cell lymphoma of mucosa-associated lymphoid tissue]] | ||
| Line 23: | Line 22: | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
*[[T-cell acute lymphoblastic leukemia]] | *[[T-cell acute lymphoblastic leukemia]] | ||
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Chronic lymphocytic leukemia - historic|Chronic lymphocytic leukemia]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 50: | Line 52: | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
| − | |||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| Line 59: | Line 60: | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:T-cell acute lymphoblastic leukemia medications]] | [[Category:T-cell acute lymphoblastic leukemia medications]] | ||
| + | |||
| + | [[Category:Chronic lymphocytic leukemia medications (historic)]] | ||
[[Category:FDA approved in 1987]] | [[Category:FDA approved in 1987]] | ||
Revision as of 13:31, 28 April 2022
General information
Class/mechanism: Synthetic antineoplastic anthracenedione, intercalates into DNA, causing crosslinking and strand breaks. Mitoxantrone inhibits topoisomerase II, which helps to uncoil and repair damaged DNA. It also has been observed to interfere with RNA and has activity against resting and proliferating cells. In vitro, it has been observed to interfere with antigen presentation; inhibit B-cell, T-cell, and macrophage proliferation; and decrease secretion of interferon gamma, tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2).[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- B-cell acute lymphoblastic leukemia
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Breast cancer
- Non-Hodgkin lymphoma
- Prostate cancer
- T-cell acute lymphoblastic leukemia
Diseases for which it was used
Patient drug information
- Mitoxantrone (Novantrone) patient drug information (Chemocare)[3]
- Mitoxantrone (Novantrone) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/23/1987: Initial FDA approval for the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias
- 11/13/1996: Approved in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.
Also known as
- Generic name: mitozantrone
- Brand names: Nitrol, Novantron, Novantrone
References
- Drugs
- Intravenous medications
- Irritant
- Anthracenedione
- Topoisomerase inhibitors
- B-cell acute lymphoblastic leukemia medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Breast cancer medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- Hodgkin lymphoma medications
- MALT lymphoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Prostate cancer medications
- T-cell acute lymphoblastic leukemia medications
- Chronic lymphocytic leukemia medications (historic)
- FDA approved in 1987